Multiple placebo-controlled trials have demonstrated that intravenous vernakalant, a novel antiarrhythmic agent, effectively converts recent-onset atrial fibrillation in ∼50% of patients within 90 min of administration. Results from the AVRO trial corroborate these findings and further show that vernakalant is superior to amiodarone in the treatment of this condition.
- Soraya M. Samii
- Gerald V. Naccarelli
